Although Canada has secured four contracts for more 190 million doses of potential COVID-19 vaccines, health officials aren’t sure how many people will need to receive it.
Deputy public health officer Dr. Howard Njoo said Tuesday (Sept. 1) that the level of vaccination to achieve community, or herd, protection varies by the disease.
“That’s still to be determined because the science is not clear on that yet,” Njoo said.
“For a very contagious disease like measles the vaccine uptake needs to be much higher to determine that level of community protection. We don’t know that yet for COVID-19.”
There are currently at least 128,948 total test positive cases of the virus in Canada, with more than 9,100 deaths.
For measles, the Canadian government has a goal of 95 per cent vaccination by 2025. According to John Hopkins University, early estimates of the virus’s infectiousness point to at least 60 to 70 per cent of the population needing to be vaccinated to achieve herd protection. A recent poll suggests that about 14 per cent of Canadians will not get the vaccine altogether, while nearly one-third will adopt a “wait and see” approach.
It’s also unclear how effective an eventual vaccine will be.
“International consensus is that we should at least look at vaccines that are around the 50 per cent vaccine efficacy mark,” chief public health officer Dr. Theresa Tam said, echoing similar statements from other public health researchers.
“This means that an individual who was vaccinated would be 50 per cent less likely to get COVID disease—or whatever the particular endpoint is that’s measured in the trial—than individuals that weren’t vaccinated,” said Dr. Ruth Karron, who leads the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health.
But Canadian health officials were sure on one point; going for a herd immunity approach by letting the disease run through the population was not effective. Tam called it an “extremely difficult strategy” because of the potential for exponential growth that could overwhelm health-care systems.
“What we do know that even in the most [COVID-19] affected parts of the world, the level of population immunity seems quite low, so getting high enough vaccine uptake is going to be quite important,” Tam said.
Currently, Canada has agreements with Johnson & Johnson, Novavax, Pfizer and Moderna, if any of the four companies develop an effective vaccine. Any vaccine will have to be approved by Health Canada before Canadians can get it.
Source: – Peace Arch News
Moderna's Covid-19 vaccine won't be ready by US election: Report – Times of India
WASHINGTON: US biotech firm Moderna won’t seek an emergency use authorization for its coronavirus vaccine before November 25, its CEO told the Financial Times on Wednesday.
The news deals a blow to President Donald Trump‘s hopes of having an injection ready before the election to give his campaign a much-needed boost.
Stephane Bancel told the newspaper: “November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA (Food and Drug Administration) – assuming that the safety data is good, i.e. a vaccine is deemed to be safe.”
Trump, whose approval has taken a hit over his handling of the Covid-19 crisis, has frequently hinted a vaccine could be ready before the November 3 vote.
This has raised concern among experts that his administration may attempt to interfere with the regulatory process for political reasons.
The Republican repeated his claim on Tuesday night, during a debate with his Democratic rival, former vice president Joe Biden.
“It’s a possibility that we’ll have the answer before November 1,” he said.
Moderna’s vaccine is one of 11 experimental vaccines in final stage trials.
Another is being developed by Pfizer, whose CEO Albert Bourla has taken the position that his company may have a clear answer about whether their shot works by October.
Most experts are skeptical of the claim, believing that the ongoing trials will not have sufficient statistical data to prove the drug’s safety and effectiveness by that time.
Speaking to the Washington Post on Tuesday, Bourla denied he was attempting to curry favor with the president by making his October claim.
“For me, the election day is an artificial day. The end of October is an artificial day. This is how we operate. If we can bring it earlier, we will,” he said.
Moderna COVID-19 vaccine appears safe, shows signs of working in older adults: study – Reuters
CHICAGO (Reuters) – Results from an early safety study of Moderna Inc’s MRNA.O coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said on Tuesday.
The study, published in the New England Journal of Medicine, offers a more complete picture of the vaccine’s safety in older adults, a group at increased risk of severe complications from COVID-19.
The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study’s lead researchers from Emory University in Atlanta, said in a phone interview.
The study was an extension of Moderna’s Phase I safety trial, first conducted in individuals aged 18-55. It tested two doses of Moderna’s vaccine – 25 micrograms and 100 micrograms – in 40 adults aged 56 to 70 and 71 and older.
Overall, the team found that in older adults who received two injections of the 100 microgram dose 28 days apart, the vaccine produced immune responses roughly in line with those seen in younger adults.
Moderna is already testing the higher dose in a large Phase III trial, the final stage before seeking emergency authorization or approval.
Side effects, which included headache, fatigue, body aches, chills and injection site pain, were deemed mainly mild to moderate.
In at least two cases, however, volunteers had severe reactions.
One developed a grade three fever, which is classified as 102.2 degrees Fahrenheit (39°C) or above, after receiving the lower vaccine dose. Another developed fatigue so severe it temporarily prevented daily activities, Anderson said.
Typically, side effects occurred soon after receiving the vaccine and resolved quickly, he said.
“This is similar to what a lot of older adults are going to experience with the high dose influenza vaccine,” Anderson said. “They might feel off or have a fever.”
Norman Hulme, a 65-year-old senior multimedia developer at Emory who took the lower dose of the vaccine, said he felt compelled to take part in the trial after watching first responders in New York and Washington State fight the virus.
“I really had no side effects at all,” said Hulme, who grew up in the New York area.
Hulme said he was aware Moderna’s vaccine employed a new technology, and that there might be a risk in taking it, but said, “somebody had to do it.”
Reporting by Julie Steenhuysen; Editing by Bill Berkrot
The financial impact of COVID-19 on Manitoba Liquor and Lotteries
Manitoba Liquor and Lotteries Corporation’s net income was $24 million below the budget, according to the province’s fiscal update.
The numbers, released Tuesday, states the lower than anticipated revenue is due to impacts from COVID-19, including declining attendance and the closure of casinos and VLT networks in March.
The Casinos of Winnipeg began experiencing declining attendance in the last month of 2019/20, and on March 18, 2020, the provincial government required all Manitoba casinos to close.
For March 2020, revenues were nearly 70 per cent lower than the same period of 2018/19.
The annual report said revenue from casinos dropped $8.6 million this year, a 3.4 per cent decline.
During the month of March, bars and restaurants across Manitoba began to close voluntarily due to reduced business, as patrons heeded physical distancing and stay-at-home recommendations. VLT revenues were 40 per cent lower compared to March 2019, and liquor sales to licensees were also down 24 per cent in March 2020 compared to the prior year.
All other liquor channels experienced strong sales in March 2020, led by Liquor Marts at 29 per cent above March 2019.
Liquor revenue jumped by $13 million, mostly from sales at Liquor Marts.
Cannabis sales nearly doubled, bringing in nearly $51 million in 2020, compared to just under $27 million.
Casinos in Manitoba began reopening on July 25.
Source: – CTV News Winnipeg
Half a million sharks may be killed to produce global Covid-19 vaccine – RFI English
Ukrainian Politics Again Get the Better of a Would-Be Reformer – Bloomberg
Social media helping First Nations push moderate livelihood – TheChronicleHerald.ca
Silver investment demand jumped 12% in 2019
Iran anticipates renewed protests amid social media shutdown
Richmond BBQ spot speaks out about coronavirus rumours Vancouver Is Awesome
- Media18 hours ago
Presidential debate: How the world’s media reacted
- Sports13 hours ago
NFL postpones Titans-Steelers game due to COVID-19 outbreak – Sportsnet.ca
- Sports17 hours ago
Eugenie Bouchard advances at French Open after three-set win over Daria Gavrilova – TSN
- Tech17 hours ago
Facebook launches cross-platform messaging on Instagram and Messenger – The Verge
- Art18 hours ago
The CERB art boom: How government cash is helping many creatives win the pandemic – National Post
- Business23 hours ago
Why some snowbirds are still heading south this winter despite COVID-19 and a closed land border
- Health22 hours ago
Lonza confident of 2020 target for Moderna COVID-19 vaccine supply – Yahoo Finance
- Business24 hours ago
Oil Prices Under Pressure As Gasoline Inventories Climb